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http://dx.doi.org/10.1016/j.cmet.2015.04.014In a recent report inCellMetabolism, Lodhi
and colleagues present intriguing findings
on the importance of fatty acidmetabolism
for the hematopoietic system (Lodhi et al.,
2015). It is convincingly shown that mice
with a conditional deficiency either in
FAS (fatty acid synthase) or in PexRAP
(peroxisomal reductase activating PPARg)
have drastically reduced levels of white
blood cells, in particular concerning
neutrophil granulocytes, but also lympho-
cytes. From the facts that PexRAP is
involved in ether phospholipid biosyn-
thesis and that Fas knockout (KO) mice
show a decrease in several choline-con-
taining ether lipid species, the authors
conclude that the observed loss of neutro-
phils is caused by the deficit in ether lipids.
This came as a surprise to us considering
that neutropenia or leukopenia has not
been described in any of the previously
established mouse models of ether lipid
deficiency or in case reports of human
patients suffering from rhizomelic chon-
drodysplasia punctata (RCDP), resulting
from inborn errors in peroxisomal ether
lipid biosynthesis.
Prompted by this apparent discrep-
ancy, we set out to clarify whether the
absence of ether lipids is indeed sufficient
to cause severe neutropenia. To this end,
we employed amousemodel of complete
ether lipid deficiency (Rodemer et al.,
2003). These animals lack glycerone-
phosphate O-acyltransferase (GNPAT;
alias: DAPAT, DHAPAT), the first enzyme
in the ether lipid biosynthesis pathway, re-
sulting in a complete inability to synthe-
size ether lipids. Strikingly, we found no
abnormalities in the counts of neutrophils,
lymphocytes, or total white blood cells in
peripheral blood from the tail of male
Gnpat KOmice (Figure S1A) or in samples
collected by cardiac puncture from fe-
male Gnpat KO and wild-type littermates
(Figure S1B).
Our results indicate that themechanism
leading to neutropenia and leukopenia,650 Cell Metabolism 21, May 5, 2015 ª2015as observed by Lodhi and collaborators,
presumably cannot be explained by ether
lipid deficiency alone. Instead, it seems
likely that other factors, apart from a
reduction in ether lipids, contribute to the
observed phenotype. PexRAP has been
described as an enzyme that catalyzes
the reduction of 1-O-alkyl-dihydroxy-
acetonephosphate (1-O-alkyl-DHAP)
(Lodhi et al., 2012). Therefore, it is
conceivable that the observed apoptosis
of neutrophils could be caused by a toxic
accumulation of the intermediate 1-O-
alkyl-DHAP due to the disruption of
PexRAP (official gene symbol: Dhrs7b).
So far, no other substrates for PexRAP
have been identified; however, these
may exist and, thus, upon PexRAP
deficiency, pathways other than ether
lipid biosynthesis could be affected. For
example, in the original description of
PexRAP function, the same authors also
reported that the levels of several non-
ether phospholipids are diminished after
knockdown of PexRAP and, more impor-
tantly, that the lack of PexRAP function
has major consequences for PPARg
signaling (Lodhi et al., 2012).
A similar phenotype concerning white
blood cell counts as in the conditional
PexRAP KO mice was also found in con-
ditional Fas KO mice. However, in these
animals, a wide variety of metabolic path-
ways and functions must be expected to
be disturbed, thereby potentially influ-
encing blood cell counts. For example,
based on the data presented by Lodhi
and collaborators, there appears to be a
general depletion of choline phospho-
lipids, which might also contribute to
membrane alterations and cause the se-
vere neutro- and leukopenia observed in
these mice.
Gnpat KO mice differ from the induc-
ible KO models described by Lodhi and
collaborators in that they represent a
model of complete ether lipid deficiency
that is present from birth on and affectsElsevier Inc.all tissues. First, it cannot be excluded
that toxicity caused by the induction of
Cre recombinase contributes to the
described hematological abnormalities.
It has been shown previously that the
activation of Cre by tamoxifen treatment
produces a variety of detrimental
changes in the hematopoietic system (Hi-
gashi et al., 2009), in particular when
analyzed within a short time frame after
the treatment. Although lower tamoxifen
concentrations, as used by Lodhi and
colleagues, may attenuate these prob-
lems (Higashi et al., 2009; Uhmann
et al., 2009), a similar effect could ac-
count for some of the alterations that
were observed in both inducible KO
models. Indeed, the authors consider
this possibility in their paper; however,
their conclusions may be challenged, as
the presented experiments allow alterna-
tive interpretations. Lodhi and collabora-
tors show results derived from heterozy-
gous mice (PexRAPflox/WT; see Table S3
in Lodhi et al., 2015), demonstrating
remarkable, even if not statistically signif-
icant, decreases in white blood cells
upon Cre induction. They attribute these
alterations to a gene dosage effect, but
in light of the observations reported
by Higashi and collaborators, toxicity
resulting from Cre activation may also
contribute to the observed phenotype.
This issue could only be solved by a
comparison of PexRAPWT/WT (CreER)
and PexRAPWT/WT (+CreER) mice.
Furthermore, the blood cell investiga-
tions in conditional PexRAP and Fas KO
mice were conducted a few days after
the initiation of tamoxifen treatment (in-
duction of the knockout), a time frame
that may not allow for blood cells and
their progenitors to adapt to the changed
condition, leading to neutrophil loss. We
cannot exclude that in Gnpat KO mice,
such adaptation processes to the condi-
tion of ether lipid deficiency occur and
counteract the loss of neutrophils and
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models. Especially in light of possible
therapeutic implications of the findings
of Lodhi and collaborators, these consid-
erations could be of high relevance.
In order to confirm the results derived
from theGnpatmousemodel, we also ob-
tained data from patients with RCDP that
had been deposited in an RCDP database
at the RhizoKids registry. Also upon in-
herited ether lipid deficiency in humans,
no signs of neutropenia or leukopenia
could be observed (Figure S1C). A trend
toward increased leukocyte and neutro-
phil levels can be explained by the fact
that the presented data were recorded in
a clinical setting and that these patients
frequently suffer from respiratory tract
infections.
Due to the potential importance of the
findings of Lodhi and colleagues for a
variety of abundant disease conditions,caution is warranted for the interpretation
of these data. Therefore, pathways other
than the disruption of ether lipid biosyn-
thesis, which—as we have demonstrated
here—alone is not sufficient to induce
severe neutropenia, may need to be
explored in further studies to understand
in greater detail the mechanisms underly-
ing the observed phenotype.
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